Data for CDC’s COVID Data Tracker site on Rates of COVID-19 Cases and Deaths by Updated (Bivalent) Booster Status. Click 'More' for important dataset description and footnotes
Webpage: https://covid.cdc.gov/covid-data-tracker/#rates-by-vaccine-status
Dataset and data visualization details:
These data were posted and archived on May 30, 2023 and reflect cases among persons with a positive specimen collection date through April 22, 2023, and deaths among persons with a positive specimen collection date through April 1, 2023. These data will no longer be updated after May 2023.
Vaccination status: A person vaccinated with at least a primary series had SARS-CoV-2 RNA or antigen detected on a respiratory specimen collected ≥14 days after verifiably completing the primary series of an FDA-authorized or approved COVID-19 vaccine. An unvaccinated person had SARS-CoV-2 RNA or antigen detected on a respiratory specimen and has not been verified to have received COVID-19 vaccine. Excluded were partially vaccinated people who received at least one FDA-authorized vaccine dose but did not complete a primary series ≥14 days before collection of a specimen where SARS-CoV-2 RNA or antigen was detected. A person vaccinated with a primary series and a monovalent booster dose had SARS-CoV-2 RNA or antigen detected on a respiratory specimen collected ≥14 days after verifiably receiving a primary series of an FDA-authorized or approved vaccine and at least one additional dose of any monovalent FDA-authorized or approved COVID-19 vaccine on or after August 13, 2021. (Note: this definition does not distinguish between vaccine recipients who are immunocompromised and are receiving an additional dose versus those who are not immunocompromised and receiving a booster dose.) A person vaccinated with a primary series and an updated (bivalent) booster dose had SARS-CoV-2 RNA or antigen detected in a respiratory specimen collected ≥14 days after verifiably receiving a primary series of an FDA-authorized or approved vaccine and an additional dose of any bivalent FDA-authorized or approved vaccine COVID-19 vaccine on or after September 1, 2022. (Note: Doses with bivalent doses reported as first or second doses are classified as vaccinated with a bivalent booster dose.) People with primary series or a monovalent booster dose were combined in the “vaccinated without an updated booster” category.
Deaths: A COVID-19–associated death occurred in a person with a documented COVID-19 diagnosis who died; health department staff reviewed to make a determination using vital records, public health investigation, or other data sources. Per the interim guidance of the Council of State and Territorial Epidemiologists (CSTE), this should include persons whose death certificate lists COVID-19 disease or SARS-CoV-2 as the underlying cause of death or as a significant condition contributing to death. Rates of COVID-19 deaths by vaccination status are primarily reported based on when the patient was tested for COVID-19. In select jurisdictions, deaths are included that are not laboratory confirmed and are reported based on alternative dates (i.e., onset date for most; or date of death or report date, where onset date is unavailable). Deaths usually occur up to 30 days after COVID-19 diagnosis.
Participating jurisdictions: Currently, these 24 health departments that regularly link their case surveillance to immunization information system data are included in these incidence rate estimates: Alabama, Arizona, Colorado, District of Columbia, Georgia, Idaho, Indiana, Kansas, Kentucky, Louisiana, Massachusetts, Michigan, Minnesota, Nebraska, New Jersey, New Mexico, New York, New York City (NY), North Carolina, Rhode Island, Tennessee, Texas, Utah, and West Virginia; 23 jurisdictions also report deaths among vaccinated and unvaccinated people. These jurisdictions represent 48% of the total U.S. population and all ten of the Health and Human Services Regions. This list will be
The COVID-19 dashboard includes data on city/town COVID-19 activity, confirmed and probable cases of COVID-19, confirmed and probable deaths related to COVID-19, and the demographic characteristics of cases and deaths.
NOTE: This dataset has been retired and marked as historical-only.
Weekly rates of COVID-19 cases, hospitalizations, and deaths among people living in Chicago by vaccination status and age.
Rates for fully vaccinated and unvaccinated begin the week ending April 3, 2021 when COVID-19 vaccines became widely available in Chicago. Rates for boosted begin the week ending October 23, 2021 after booster shots were recommended by the Centers for Disease Control and Prevention (CDC) for adults 65+ years old and adults in certain populations and high risk occupational and institutional settings who received Pfizer or Moderna for their primary series or anyone who received the Johnson & Johnson vaccine.
Chicago residency is based on home address, as reported in the Illinois Comprehensive Automated Immunization Registry Exchange (I-CARE) and Illinois National Electronic Disease Surveillance System (I-NEDSS).
Outcomes: • Cases: People with a positive molecular (PCR) or antigen COVID-19 test result from an FDA-authorized COVID-19 test that was reported into I-NEDSS. A person can become re-infected with SARS-CoV-2 over time and so may be counted more than once in this dataset. Cases are counted by week the test specimen was collected. • Hospitalizations: COVID-19 cases who are hospitalized due to a documented COVID-19 related illness or who are admitted for any reason within 14 days of a positive SARS-CoV-2 test. Hospitalizations are counted by week of hospital admission. • Deaths: COVID-19 cases who died from COVID-19-related health complications as determined by vital records or a public health investigation. Deaths are counted by week of death.
Vaccination status: • Fully vaccinated: Completion of primary series of a U.S. Food and Drug Administration (FDA)-authorized or approved COVID-19 vaccine at least 14 days prior to a positive test (with no other positive tests in the previous 45 days). • Boosted: Fully vaccinated with an additional or booster dose of any FDA-authorized or approved COVID-19 vaccine received at least 14 days prior to a positive test (with no other positive tests in the previous 45 days). • Unvaccinated: No evidence of having received a dose of an FDA-authorized or approved vaccine prior to a positive test.
CLARIFYING NOTE: Those who started but did not complete all recommended doses of an FDA-authorized or approved vaccine prior to a positive test (i.e., partially vaccinated) are excluded from this dataset.
Incidence rates for fully vaccinated but not boosted people (Vaccinated columns) are calculated as total fully vaccinated but not boosted with outcome divided by cumulative fully vaccinated but not boosted at the end of each week. Incidence rates for boosted (Boosted columns) are calculated as total boosted with outcome divided by cumulative boosted at the end of each week. Incidence rates for unvaccinated (Unvaccinated columns) are calculated as total unvaccinated with outcome divided by total population minus cumulative boosted, fully, and partially vaccinated at the end of each week. All rates are multiplied by 100,000.
Incidence rate ratios (IRRs) are calculated by dividing the weekly incidence rates among unvaccinated people by those among fully vaccinated but not boosted and boosted people.
Overall age-adjusted incidence rates and IRRs are standardized using the 2000 U.S. Census standard population.
Population totals are from U.S. Census Bureau American Community Survey 1-year estimates for 2019.
All data are provisional and subject to change. Information is updated as additional details are received and it is, in fact, very common for recent dates to be incomplete and to be updated as time goes on. This dataset reflects data known to CDPH at the time when the dataset is updated each week.
Numbers in this dataset may differ from other public sources due to when data are reported and how City of Chicago boundaries are defined.
For all datasets related to COVID-19, see https://data.cityofchic
The New York Times is releasing a series of data files with cumulative counts of coronavirus cases in the United States, at the state and county level, over time. We are compiling this time series data from state and local governments and health departments in an attempt to provide a complete record of the ongoing outbreak.
Since late January, The Times has tracked cases of coronavirus in real time as they were identified after testing. Because of the widespread shortage of testing, however, the data is necessarily limited in the picture it presents of the outbreak.
We have used this data to power our maps and reporting tracking the outbreak, and it is now being made available to the public in response to requests from researchers, scientists and government officials who would like access to the data to better understand the outbreak.
The data begins with the first reported coronavirus case in Washington State on Jan. 21, 2020. We will publish regular updates to the data in this repository.
As of January 1, 2025, the number of active coronavirus (COVID-19) infections in Italy was approximately 218,000. Among these, 42 infected individuals were being treated in intensive care units. Another 1,332 individuals infected with the coronavirus were hospitalized with symptoms, while approximately 217,000 thousand were in isolation at home. The total number of coronavirus cases in Italy reached over 26.9 million (including active cases, individuals who recovered, and individuals who died) as of the same date. The region mostly hit by the spread of the virus was Lombardy, which counted almost 4.4 million cases.For a global overview, visit Statista's webpage exclusively dedicated to coronavirus, its development, and its impact.
Data for CDC’s COVID Data Tracker site on Rates of COVID-19 Cases and Deaths by Vaccination Status.
Click 'More' for important dataset description and footnotes
Dataset and data visualization details:
These data were posted on October 21, 2022, archived on November 18, 2022, and revised on February 22, 2023. These data reflect cases among persons with a positive specimen collection date through September 24, 2022, and deaths among persons with a positive specimen collection date through September 3, 2022.
Vaccination status: A person vaccinated with a primary series had SARS-CoV-2 RNA or antigen detected on a respiratory specimen collected ≥14 days after verifiably completing the primary series of an FDA-authorized or approved COVID-19 vaccine. An unvaccinated person had SARS-CoV-2 RNA or antigen detected on a respiratory specimen and has not been verified to have received COVID-19 vaccine. Excluded were partially vaccinated people who received at least one FDA-authorized vaccine dose but did not complete a primary series ≥14 days before collection of a specimen where SARS-CoV-2 RNA or antigen was detected.
Additional or booster dose: A person vaccinated with a primary series and an additional or booster dose had SARS-CoV-2 RNA or antigen detected on a respiratory specimen collected ≥14 days after receipt of an additional or booster dose of any COVID-19 vaccine on or after August 13, 2021. For people ages 18 years and older, data are graphed starting the week including September 24, 2021, when a COVID-19 booster dose was first recommended by CDC for adults 65+ years old and people in certain populations and high risk occupational and institutional settings. For people ages 12-17 years, data are graphed starting the week of December 26, 2021, 2 weeks after the first recommendation for a booster dose for adolescents ages 16-17 years. For people ages 5-11 years, data are included starting the week of June 5, 2022, 2 weeks after the first recommendation for a booster dose for children aged 5-11 years. For people ages 50 years and older, data on second booster doses are graphed starting the week including March 29, 2022, when the recommendation was made for second boosters. Vertical lines represent dates when changes occurred in U.S. policy for COVID-19 vaccination (details provided above). Reporting is by primary series vaccine type rather than additional or booster dose vaccine type. The booster dose vaccine type may be different than the primary series vaccine type.
** Because data on the immune status of cases and associated deaths are unavailable, an additional dose in an immunocompromised person cannot be distinguished from a booster dose. This is a relevant consideration because vaccines can be less effective in this group.
Deaths: A COVID-19–associated death occurred in a person with a documented COVID-19 diagnosis who died; health department staff reviewed to make a determination using vital records, public health investigation, or other data sources. Rates of COVID-19 deaths by vaccination status are reported based on when the patient was tested for COVID-19, not the date they died. Deaths usually occur up to 30 days after COVID-19 diagnosis.
Participating jurisdictions: Currently, these 31 health departments that regularly link their case surveillance to immunization information system data are included in these incidence rate estimates: Alabama, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Idaho, Indiana, Kansas, Kentucky, Louisiana, Massachusetts, Michigan, Minnesota, Nebraska, New Jersey, New Mexico, New York, New York City (New York), North Carolina, Philadelphia (Pennsylvania), Rhode Island, South Dakota, Tennessee, Texas, Utah, Washington, and West Virginia; 30 jurisdictions also report deaths among vaccinated and unvaccinated people. These jurisdictions represent 72% of the total U.S. population and all ten of the Health and Human Services Regions. Data on cases
Splitgraph serves as an HTTP API that lets you run SQL queries directly on this data to power Web applications. For example:
See the Splitgraph documentation for more information.
As of January 1, 2025, the total number of coronavirus (COVID-19) cases in Italy amounted to over 26.9 million, approximately 218,000 of which were active cases. Moreover, the number of people who recovered or were discharged from hospital after contracting the virus reached over 26.5 million, while the number of deceased was equal to 198,638. For a global overview, visit Statista's webpage exclusively dedicated to coronavirus, its development, and its impact.
Reporting of new Aggregate Case and Death Count data was discontinued May 11, 2023, with the expiration of the COVID-19 public health emergency declaration. This dataset will receive a final update on June 1, 2023, to reconcile historical data through May 10, 2023, and will remain publicly available.
Aggregate Data Collection Process Since the start of the COVID-19 pandemic, data have been gathered through a robust process with the following steps:
Methodology Changes Several differences exist between the current, weekly-updated dataset and the archived version:
Confirmed and Probable Counts In this dataset, counts by jurisdiction are not displayed by confirmed or probable status. Instead, confirmed and probable cases and deaths are included in the Total Cases and Total Deaths columns, when available. Not all jurisdictions report probable cases and deaths to CDC.* Confirmed and probable case definition criteria are described here:
Council of State and Territorial Epidemiologists (ymaws.com).
Deaths CDC reports death data on other sections of the website: CDC COVID Data Tracker: Home, CDC COVID Data Tracker: Cases, Deaths, and Testing, and NCHS Provisional Death Counts. Information presented on the COVID Data Tracker pages is based on the same source (to
Daily count of NYC residents who tested positive for SARS-CoV-2, who were hospitalized with COVID-19, and deaths among COVID-19 patients.
Note that this dataset currently pulls from https://raw.githubusercontent.com/nychealth/coronavirus-data/master/trends/data-by-day.csv on a daily basis.
Data for CDC’s COVID Data Tracker site on Rates of COVID-19 Cases and Deaths by Vaccination Status. Click 'More' for important dataset description and footnotes
Dataset and data visualization details: These data were posted on October 21, 2022, archived on November 18, 2022, and revised on February 22, 2023. These data reflect cases among persons with a positive specimen collection date through September 24, 2022, and deaths among persons with a positive specimen collection date through September 3, 2022.
Vaccination status: A person vaccinated with a primary series had SARS-CoV-2 RNA or antigen detected on a respiratory specimen collected ≥14 days after verifiably completing the primary series of an FDA-authorized or approved COVID-19 vaccine. An unvaccinated person had SARS-CoV-2 RNA or antigen detected on a respiratory specimen and has not been verified to have received COVID-19 vaccine. Excluded were partially vaccinated people who received at least one FDA-authorized vaccine dose but did not complete a primary series ≥14 days before collection of a specimen where SARS-CoV-2 RNA or antigen was detected. Additional or booster dose: A person vaccinated with a primary series and an additional or booster dose had SARS-CoV-2 RNA or antigen detected on a respiratory specimen collected ≥14 days after receipt of an additional or booster dose of any COVID-19 vaccine on or after August 13, 2021. For people ages 18 years and older, data are graphed starting the week including September 24, 2021, when a COVID-19 booster dose was first recommended by CDC for adults 65+ years old and people in certain populations and high risk occupational and institutional settings. For people ages 12-17 years, data are graphed starting the week of December 26, 2021, 2 weeks after the first recommendation for a booster dose for adolescents ages 16-17 years. For people ages 5-11 years, data are included starting the week of June 5, 2022, 2 weeks after the first recommendation for a booster dose for children aged 5-11 years. For people ages 50 years and older, data on second booster doses are graphed starting the week including March 29, 2022, when the recommendation was made for second boosters. Vertical lines represent dates when changes occurred in U.S. policy for COVID-19 vaccination (details provided above). Reporting is by primary series vaccine type rather than additional or booster dose vaccine type. The booster dose vaccine type may be different than the primary series vaccine type. ** Because data on the immune status of cases and associated deaths are unavailable, an additional dose in an immunocompromised person cannot be distinguished from a booster dose. This is a relevant consideration because vaccines can be less effective in this group. Deaths: A COVID-19–associated death occurred in a person with a documented COVID-19 diagnosis who died; health department staff reviewed to make a determination using vital records, public health investigation, or other data sources. Rates of COVID-19 deaths by vaccination status are reported based on when the patient was tested for COVID-19, not the date they died. Deaths usually occur up to 30 days after COVID-19 diagnosis. Participating jurisdictions: Currently, these 31 health departments that regularly link their case surveillance to immunization information system data are included in these incidence rate estimates: Alabama, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Idaho, Indiana, Kansas, Kentucky, Louisiana, Massachusetts, Michigan, Minnesota, Nebraska, New Jersey, New Mexico, New York, New York City (New York), North Carolina, Philadelphia (Pennsylvania), Rhode Island, South Dakota, Tennessee, Texas, Utah, Washington, and West Virginia; 30 jurisdictions also report deaths among vaccinated and unvaccinated people. These jurisdictions represent 72% of the total U.S. population and all ten of the Health and Human Services Regions. Data on cases
This dataset includes the number of COVID-19 infections, hospitalizations, and deaths for each health region in Virginia by the week of onset/specimen collection and by vaccination status.
Note: As of 10/28/2021 this dataset is no longer being updated. For more information about COVID-19 cases by vaccination status, visit the Department of Public Health's daily report here: https://data.ct.gov/stories/s/q5as-kyim Cases of COVID-19 by vaccination status by weekly reporting period. All data in this report are preliminary; data for previous dates will be updated as new reports are received and data errors are corrected. Since February 2021, cases of COVID-19 among fully vaccinated persons (e.g., vaccine breakthrough cases) were identified based on a medical provider report to DPH identifying such cases. Recently, DPH developed a process that matches COVID-19 case data with the vaccine registry to determine which cases meet the definition of being fully vaccinated and are also vaccine breakthrough cases. A case of COVID-19 in a fully vaccinated person (e.g., vaccine breakthrough case) is defined as a person who has a positive PCR/NAAT or antigen test in a respiratory specimen collected ≥14 days after completing the final dose of an FDA-authorized or approved COVID-19 vaccine series and who did not have a previously positive COVID-19 test <45 days prior to the positive test currently under investigation. This newer process provides more accurate and complete data on the vaccine status of persons who have tested positive for COVID-19.
Notice of data discontinuation: Since the start of the pandemic, AP has reported case and death counts from data provided by Johns Hopkins University. Johns Hopkins University has announced that they will stop their daily data collection efforts after March 10. As Johns Hopkins stops providing data, the AP will also stop collecting daily numbers for COVID cases and deaths. The HHS and CDC now collect and visualize key metrics for the pandemic. AP advises using those resources when reporting on the pandemic going forward.
April 9, 2020
April 20, 2020
April 29, 2020
September 1st, 2020
February 12, 2021
new_deaths
column.February 16, 2021
The AP is using data collected by the Johns Hopkins University Center for Systems Science and Engineering as our source for outbreak caseloads and death counts for the United States and globally.
The Hopkins data is available at the county level in the United States. The AP has paired this data with population figures and county rural/urban designations, and has calculated caseload and death rates per 100,000 people. Be aware that caseloads may reflect the availability of tests -- and the ability to turn around test results quickly -- rather than actual disease spread or true infection rates.
This data is from the Hopkins dashboard that is updated regularly throughout the day. Like all organizations dealing with data, Hopkins is constantly refining and cleaning up their feed, so there may be brief moments where data does not appear correctly. At this link, you’ll find the Hopkins daily data reports, and a clean version of their feed.
The AP is updating this dataset hourly at 45 minutes past the hour.
To learn more about AP's data journalism capabilities for publishers, corporations and financial institutions, go here or email kromano@ap.org.
Use AP's queries to filter the data or to join to other datasets we've made available to help cover the coronavirus pandemic
Filter cases by state here
Rank states by their status as current hotspots. Calculates the 7-day rolling average of new cases per capita in each state: https://data.world/associatedpress/johns-hopkins-coronavirus-case-tracker/workspace/query?queryid=481e82a4-1b2f-41c2-9ea1-d91aa4b3b1ac
Find recent hotspots within your state by running a query to calculate the 7-day rolling average of new cases by capita in each county: https://data.world/associatedpress/johns-hopkins-coronavirus-case-tracker/workspace/query?queryid=b566f1db-3231-40fe-8099-311909b7b687&showTemplatePreview=true
Join county-level case data to an earlier dataset released by AP on local hospital capacity here. To find out more about the hospital capacity dataset, see the full details.
Pull the 100 counties with the highest per-capita confirmed cases here
Rank all the counties by the highest per-capita rate of new cases in the past 7 days here. Be aware that because this ranks per-capita caseloads, very small counties may rise to the very top, so take into account raw caseload figures as well.
The AP has designed an interactive map to track COVID-19 cases reported by Johns Hopkins.
@(https://datawrapper.dwcdn.net/nRyaf/15/)
<iframe title="USA counties (2018) choropleth map Mapping COVID-19 cases by county" aria-describedby="" id="datawrapper-chart-nRyaf" src="https://datawrapper.dwcdn.net/nRyaf/10/" scrolling="no" frameborder="0" style="width: 0; min-width: 100% !important;" height="400"></iframe><script type="text/javascript">(function() {'use strict';window.addEventListener('message', function(event) {if (typeof event.data['datawrapper-height'] !== 'undefined') {for (var chartId in event.data['datawrapper-height']) {var iframe = document.getElementById('datawrapper-chart-' + chartId) || document.querySelector("iframe[src*='" + chartId + "']");if (!iframe) {continue;}iframe.style.height = event.data['datawrapper-height'][chartId] + 'px';}}});})();</script>
Johns Hopkins timeseries data - Johns Hopkins pulls data regularly to update their dashboard. Once a day, around 8pm EDT, Johns Hopkins adds the counts for all areas they cover to the timeseries file. These counts are snapshots of the latest cumulative counts provided by the source on that day. This can lead to inconsistencies if a source updates their historical data for accuracy, either increasing or decreasing the latest cumulative count. - Johns Hopkins periodically edits their historical timeseries data for accuracy. They provide a file documenting all errors in their timeseries files that they have identified and fixed here
This data should be credited to Johns Hopkins University COVID-19 tracking project
Note: This dataset is no longer being updated due to the end of the COVID-19 Public Health Emergency.
The California Department of Public Health (CDPH) is identifying vaccination status of COVID-19 cases, hospitalizations, and deaths by analyzing the state immunization registry and registry of confirmed COVID-19 cases. Post-vaccination cases are individuals who have a positive SARS-Cov-2 molecular test (e.g. PCR) at least 14 days after they have completed their primary vaccination series.
Tracking cases of COVID-19 that occur after vaccination is important for monitoring the impact of immunization campaigns. While COVID-19 vaccines are safe and effective, some cases are still expected in persons who have been vaccinated, as no vaccine is 100% effective. For more information, please see https://www.cdph.ca.gov/Programs/CID/DCDC/Pages/COVID-19/Post-Vaccine-COVID19-Cases.aspx
Post-vaccination infection data is updated monthly and includes data on cases, hospitalizations, and deaths among the unvaccinated and the vaccinated. Partially vaccinated individuals are excluded. To account for reporting and processing delays, there is at least a one-month lag in provided data (for example data published on 9/9/22 will include data through 7/31/22).
Notes:
On September 9, 2022, the post-vaccination data has been changed to compare unvaccinated with those with at least a primary series completed for persons age 5+. These data will be updated monthly (first Thursday of the month) and include at least a one month lag.
On February 2, 2022, the post-vaccination data has been changed to distinguish between vaccination with a primary series only versus vaccinated and boosted. The previous dataset has been uploaded as an archived table. Additionally, the lag on this data has been extended to 14 days.
On November 29, 2021, the denominator for calculating vaccine coverage has been changed from age 16+ to age 12+ to reflect new vaccine eligibility criteria. The previous dataset based on age 16+ denominators has been uploaded as an archived table.
Open Government Licence - Canada 2.0https://open.canada.ca/en/open-government-licence-canada
License information was derived automatically
This dataset compiles daily snapshots of publicly reported data on 2019 Novel Coronavirus (COVID-19) testing in Ontario. Learn how the Government of Ontario is helping to keep Ontarians safe during the 2019 Novel Coronavirus outbreak. Data includes: * reporting date * reporting Public Health Unit (PHU) * case outcomes (active, resolutions and deaths) The last update of this file will occur on Thursday December 1, 2022. For more information about COVID-19 cases and deaths by public health unit, please consult the Public Health Ontario COVID-19 data tool The methodology used to count COVID-19 deaths has changed to exclude deaths not caused by COVID. This impacts data captured in the columns “RESOLVED_CASES” and “DEATHS” starting with the file posted on March 11, 2022. Two new columns have been added to the file “ARCHIVED_RESOLVED_CASES” and “ARCHIVED_DEATHS” which represent the data that were posted publicly prior to the methodological change. This dataset is subject to change. Please review the daily epidemiologic summaries for information on variables, methodology, and technical considerations.
Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
City level open access data from 26 States and the Federal District and from the Brazilian Institute of Geography and Statistics (IBGE) [20], the Department of Informatics of Brazilian Public Health System – DATASUS, Ministry of Health, the Brazilian Agricultural Research Corporation (Embrapa) and from Brazil.io. Data from all 5,570 cities in Brazil were included in the analysis. COVID-19 data included cases and deaths reported between February 26th, 2020 and February 4th, 2021. The following outcomes were computed: a) days between the first case in Brazil until the first case in the city; b) days between the first case in the city until the day when 1,000 cases were reported; and c) days between the first death in city until the day when 50 deaths inhabitants were reported. Descriptive analyses were performed on the following: proportion of cities reaching 1,000 cases; number of cases at three, six, nine and 12 months after first case; cities reporting at least one COVID-19 related death; number of COVID-19 related deaths at three, six, nine and 12 months after first death in the country. All incidence data is adjusted for 100,000 inhabitants.The following covariates were included: a) geographic region where the city is located (Midwest, North, Northeast, Southeast and South), metropolitan city (no/yes) and urban or rural; b) social and environmental city characteristics [total area (Km2), urban area (Km2), population size (inhabitants), population living within urban area (inhabitants), population older than 60 years (%), indigenous population (%), black population (%), illiterate older than 25 years (%) and city in extreme poverty (no/yes)]; c) housing conditions [household with density >2 per dormitory (%), household with garbage collection (%), household connected to the water supply system (%) and household connected to the sewer system (%)]; d) job characteristics [commerce (%) and informal workers (%)]; e) socioeconomic and inequalities characteristics [GINI index; income per capita; poor or extremely poor (%) and households in informal urban settlements (%)]; f) health services access and coverage [number of National Public Health System (SUS) physicians per inhabitants (100,000 inhabitants), number of SUS nurses per inhabitants (100,000 inhabitants), number of intensive care units or ICU per inhabitants (100,000 inhabitants). All health services access and coverage variables were standardized using z-scores, combined into one single variable categorized into tertiles.
As of November 15, 2023, there have been 11,619,990 total infections of coronavirus in Vietnam. At the moment, 10,639,962 patients have recovered. Vietnam has recorded 43,206 deaths related to the COVID-19 pandemic so far, most of which occurred during the current outbreaks in Ha Noi.
COVID-19 development in Vietnam
On January 30, 2020, the first two patients with COVID-19 in Vietnam were diagnosed. They were a male from Wuhan and his son, who was living in Long An and whom the father was visiting. Both father and son were tested positive and treated in a hospital. Although the number of infections was contained after that, travel activities have again led to a steady increase in COVID-19 cases. Patient 17, who returned from Europe, as well as patient 34, who returned from Washington via Qatar, were in contact with several citizens in Vietnam before the infection was determined, which started a chain of infections.
Measures against COVID-19 in Vietnam
Beginning April 1, 2020, Vietnam went into 15 days of nationwide social distancing and self-isolation after the latest directive signed by the Prime Minister. Until now, there have been three major outbreaks happening across the country, leading to several lockdowns in some regions. Vietnam was one of the first countries to close its border and suspended international commercial flights in March 2020. Almost all visitors coming to Vietnam currently need pre-approvals from the Vietnamese embassy and have to go through centralized quarantine for 14 days. The country also started its vaccination campaign in March 2021, with the front-line health care workers being the first group to be vaccinated. Additionally, Vietnam has also been developing its own vaccines, which are expected to be in use at the end of 2021.
Data for CDC’s COVID Data Tracker site on Rates of COVID-19 Cases and Deaths by Vaccination Status. Click 'More' for important dataset description and footnotes
Dataset and data visualization details: These data were posted on October 21, 2022, archived on November 18, 2022, and revised on February 22, 2023. These data reflect cases among persons with a positive specimen collection date through September 24, 2022, and deaths among persons with a positive specimen collection date through September 3, 2022.
Vaccination status: A person vaccinated with a primary series had SARS-CoV-2 RNA or antigen detected on a respiratory specimen collected ≥14 days after verifiably completing the primary series of an FDA-authorized or approved COVID-19 vaccine. An unvaccinated person had SARS-CoV-2 RNA or antigen detected on a respiratory specimen and has not been verified to have received COVID-19 vaccine. Excluded were partially vaccinated people who received at least one FDA-authorized vaccine dose but did not complete a primary series ≥14 days before collection of a specimen where SARS-CoV-2 RNA or antigen was detected. Additional or booster dose: A person vaccinated with a primary series and an additional or booster dose had SARS-CoV-2 RNA or antigen detected on a respiratory specimen collected ≥14 days after receipt of an additional or booster dose of any COVID-19 vaccine on or after August 13, 2021. For people ages 18 years and older, data are graphed starting the week including September 24, 2021, when a COVID-19 booster dose was first recommended by CDC for adults 65+ years old and people in certain populations and high risk occupational and institutional settings. For people ages 12-17 years, data are graphed starting the week of December 26, 2021, 2 weeks after the first recommendation for a booster dose for adolescents ages 16-17 years. For people ages 5-11 years, data are included starting the week of June 5, 2022, 2 weeks after the first recommendation for a booster dose for children aged 5-11 years. For people ages 50 years and older, data on second booster doses are graphed starting the week including March 29, 2022, when the recommendation was made for second boosters. Vertical lines represent dates when changes occurred in U.S. policy for COVID-19 vaccination (details provided above). Reporting is by primary series vaccine type rather than additional or booster dose vaccine type. The booster dose vaccine type may be different than the primary series vaccine type. ** Because data on the immune status of cases and associated deaths are unavailable, an additional dose in an immunocompromised person cannot be distinguished from a booster dose. This is a relevant consideration because vaccines can be less effective in this group. Deaths: A COVID-19–associated death occurred in a person with a documented COVID-19 diagnosis who died; health department staff reviewed to make a determination using vital records, public health investigation, or other data sources. Rates of COVID-19 deaths by vaccination status are reported based on when the patient was tested for COVID-19, not the date they died. Deaths usually occur up to 30 days after COVID-19 diagnosis. Participating jurisdictions: Currently, these 31 health departments that regularly link their case surveillance to immunization information system data are included in these incidence rate estimates: Alabama, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Idaho, Indiana, Kansas, Kentucky, Louisiana, Massachusetts, Michigan, Minnesota, Nebraska, New Jersey, New Mexico, New York, New York City (New York), North Carolina, Philadelphia (Pennsylvania), Rhode Island, South Dakota, Tennessee, Texas, Utah, Washington, and West Virginia; 30 jurisdictions also report deaths among vaccinated and unvaccinated people. These jurisdictions represent 72% of the total U.S. population and all ten of the Health and Human Services Regions. Data on cases
As of February 2025, a total of *** clinical studies on COVID-19 had been completed in Mexico. Meanwhile, another ** COVID-19 clinical trials were recruiting participants. As of June 3, 2022, there were over ***** drugs and vaccines in development targeting the coronavirus disease (COVID-19) worldwide.
2019 Novel Coronavirus COVID-19 (2019-nCoV) Visual Dashboard and Map:
https://www.arcgis.com/apps/opsdashboard/index.html#/bda7594740fd40299423467b48e9ecf6
Downloadable data:
https://github.com/CSSEGISandData/COVID-19
Additional Information about the Visual Dashboard:
https://systems.jhu.edu/research/public-health/ncov
Data for CDC’s COVID Data Tracker site on Rates of COVID-19 Cases and Deaths by Updated (Bivalent) Booster Status. Click 'More' for important dataset description and footnotes
Webpage: https://covid.cdc.gov/covid-data-tracker/#rates-by-vaccine-status
Dataset and data visualization details:
These data were posted and archived on May 30, 2023 and reflect cases among persons with a positive specimen collection date through April 22, 2023, and deaths among persons with a positive specimen collection date through April 1, 2023. These data will no longer be updated after May 2023.
Vaccination status: A person vaccinated with at least a primary series had SARS-CoV-2 RNA or antigen detected on a respiratory specimen collected ≥14 days after verifiably completing the primary series of an FDA-authorized or approved COVID-19 vaccine. An unvaccinated person had SARS-CoV-2 RNA or antigen detected on a respiratory specimen and has not been verified to have received COVID-19 vaccine. Excluded were partially vaccinated people who received at least one FDA-authorized vaccine dose but did not complete a primary series ≥14 days before collection of a specimen where SARS-CoV-2 RNA or antigen was detected. A person vaccinated with a primary series and a monovalent booster dose had SARS-CoV-2 RNA or antigen detected on a respiratory specimen collected ≥14 days after verifiably receiving a primary series of an FDA-authorized or approved vaccine and at least one additional dose of any monovalent FDA-authorized or approved COVID-19 vaccine on or after August 13, 2021. (Note: this definition does not distinguish between vaccine recipients who are immunocompromised and are receiving an additional dose versus those who are not immunocompromised and receiving a booster dose.) A person vaccinated with a primary series and an updated (bivalent) booster dose had SARS-CoV-2 RNA or antigen detected in a respiratory specimen collected ≥14 days after verifiably receiving a primary series of an FDA-authorized or approved vaccine and an additional dose of any bivalent FDA-authorized or approved vaccine COVID-19 vaccine on or after September 1, 2022. (Note: Doses with bivalent doses reported as first or second doses are classified as vaccinated with a bivalent booster dose.) People with primary series or a monovalent booster dose were combined in the “vaccinated without an updated booster” category.
Deaths: A COVID-19–associated death occurred in a person with a documented COVID-19 diagnosis who died; health department staff reviewed to make a determination using vital records, public health investigation, or other data sources. Per the interim guidance of the Council of State and Territorial Epidemiologists (CSTE), this should include persons whose death certificate lists COVID-19 disease or SARS-CoV-2 as the underlying cause of death or as a significant condition contributing to death. Rates of COVID-19 deaths by vaccination status are primarily reported based on when the patient was tested for COVID-19. In select jurisdictions, deaths are included that are not laboratory confirmed and are reported based on alternative dates (i.e., onset date for most; or date of death or report date, where onset date is unavailable). Deaths usually occur up to 30 days after COVID-19 diagnosis.
Participating jurisdictions: Currently, these 24 health departments that regularly link their case surveillance to immunization information system data are included in these incidence rate estimates: Alabama, Arizona, Colorado, District of Columbia, Georgia, Idaho, Indiana, Kansas, Kentucky, Louisiana, Massachusetts, Michigan, Minnesota, Nebraska, New Jersey, New Mexico, New York, New York City (NY), North Carolina, Rhode Island, Tennessee, Texas, Utah, and West Virginia; 23 jurisdictions also report deaths among vaccinated and unvaccinated people. These jurisdictions represent 48% of the total U.S. population and all ten of the Health and Human Services Regions. This list will be